Overactive Bladder When First-Line Pharmacotherapy Has Not Achieved Adequate Symptom Control

This protocol is for patients with overactive bladder who have already completed a trial of first-line oral pharmacotherapy but did not achieve adequate improvement — or did not tolerate the medication — within the expected 4–8 week assessment window.

Previous treatment & failure condition

First-line management consisted of oral pharmacotherapy with an antimuscarinic medication or a beta-3 agonist (preferably extended-release formulations) targeting improvement in urinary urgency, frequency, and urgency urinary incontinence. When those goals were not met within 4–8 weeks of initiating treatment, or the medication was not tolerated, escalation to the next step is warranted.

Next-line approach (overview only)

The next step may involve switching to a different agent — within the same class or a different pharmacological class — or, in appropriate cases, a combination approach drawing on more than one class of medication. The treatment goal is meaningful improvement in incontinence episodes and micturition frequency. The full protocol specifies which options apply and in what sequence.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/JU.0000000000003985

In patients with OAB who experience intolerable side effects or who do not achieve adequate improvement with an OAB medication, clinicians may offer a different medication in the same class or different class of medication to obtain greater tolerability and/or efficacy.

In patients with OAB who do not achieve adequate improvement with a single OAB medication, clinicians may offer combination therapy with a medication from a different class.

Combination therapy was significantly superior to mirabegron and solifenacin alone for the number of incontinence episodes and micturitions.

View source ↗